83 related articles for article (PubMed ID: 21778320)
1. The mutational profile of sporadic epithelial ovarian carcinoma.
Kalamanathan S; Bates V; Lord R; Green JA
Anticancer Res; 2011 Aug; 31(8):2661-8. PubMed ID: 21778320
[TBL] [Abstract][Full Text] [Related]
2. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
4. A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes.
Russell SE; McCluggage WG
J Pathol; 2004 Jun; 203(2):617-9. PubMed ID: 15141374
[TBL] [Abstract][Full Text] [Related]
5. Improved survival in women with BRCA-associated ovarian carcinoma.
Cass I; Baldwin RL; Varkey T; Moslehi R; Narod SA; Karlan BY
Cancer; 2003 May; 97(9):2187-95. PubMed ID: 12712470
[TBL] [Abstract][Full Text] [Related]
6. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract][Full Text] [Related]
7. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
8. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of TP53 and p21 in familial and sporadic ovarian cancer in Japan.
Amikura T; Sekine M; Hirai Y; Fujimoto S; Hatae M; Kobayashi I; Fujii T; Nagata I; Ushijima K; Obata K; Suzuki M; Yoshinaga M; Umesaki N; Satoh S; Enomoto T; Motoyama S; Nishino K; Haino K; Tanaka K;
Gynecol Oncol; 2006 Feb; 100(2):365-71. PubMed ID: 16337994
[TBL] [Abstract][Full Text] [Related]
10. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
[TBL] [Abstract][Full Text] [Related]
11. Origins and molecular pathology of ovarian cancer.
Bell DA
Mod Pathol; 2005 Feb; 18 Suppl 2():S19-32. PubMed ID: 15761464
[TBL] [Abstract][Full Text] [Related]
12. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group.
Pharoah PD; Easton DF; Stockton DL; Gayther S; Ponder BA
Cancer Res; 1999 Feb; 59(4):868-71. PubMed ID: 10029077
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers.
Rhei E; Bogomolniy F; Federici MG; Maresco DL; Offit K; Robson ME; Saigo PE; Boyd J
Cancer Res; 1998 Aug; 58(15):3193-6. PubMed ID: 9699640
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
15. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
16. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
Jamieson S; Alexiadis M; Fuller PJ
Gynecol Oncol; 2004 Dec; 95(3):603-9. PubMed ID: 15581971
[TBL] [Abstract][Full Text] [Related]
17. Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
Köbel M; Huntsman D; Gilks CB
Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886
[TBL] [Abstract][Full Text] [Related]
18. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
20. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.
Werness BA; Ramus SJ; DiCioccio RA; Whittemore AS; Garlinghouse-Jones K; Oakley-Girvan I; Tsukada Y; Harrington P; Gayther SA; Ponder BA; Piver MS
Int J Gynecol Pathol; 2004 Jan; 23(1):29-34. PubMed ID: 14668547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]